TP53 and acute myeloid leukemia: It is also noteworthy that the molecular landscape of AML with IDH1 mutations observed at R/R disease under chemotherapy selection pressure differs from diagnosis with an increased frequency of SRSF2, ASXL1, RUNX1, NRAS, and TP53 co‐occurring mutations [49, 53].